Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial

Journal:
Nature Medicine
Published:
Affiliations:
23
Authors:
25
Institutions Authors Share
AstraZeneca United States, United States of America (USA)
6.000000
0.24
AstraZeneca Cambridge, United Kingdom (UK)
2.000000
0.08
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
0.04
Institute for Research and Innovation in Biomedicine (IRIB), France
1.000000
0.04
Hospital Clínico Universitario de Valencia, Spain
1.000000
0.04
Hôpital d'instruction des armées Sainte-Anne, France
1.000000
0.04
University of Florence (UNIFI), Italy
1.000000
0.04
CHU Limoges, France
1.000000
0.04
Centre Hospitalier de Cornouaille, France
1.000000
0.04
Seoul National University Hospital (SNUH), South Korea
1.000000
0.04
Hospital de Santa Cruz, Portugal
1.000000
0.04
Hospital Universitario Puerta de Hierro Majadahonda, UAM, Spain
1.000000
0.04
Asan Medical Center (AMC), South Korea
1.000000
0.04
University Hospital "Santa Maria della Misericordia", Italy
1.000000
0.04
Foch Hospital, France
1.000000
0.04
Laval University (UL), Canada
1.000000
0.04
The University of Dublin, Ireland
1.000000
0.04
University of Padova (UNIPD), Italy
0.500000
0.02
IRCCS Istituto Oncologico Veneto (IOV), Italy
0.500000
0.02
University of Montreal (UdeM), Canada
0.500000
0.02
Hospital of the University of Montreal (CHUM), Canada
0.500000
0.02